ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Landscape of Hypertension Treatment in Former Kidney Donors.

L. Ferrara, O. Sanchez, D. Berglund, A. Matas, H. Ibrahim.

U of MN, Mpls.

Meeting: 2016 American Transplant Congress

Abstract number: A141

Keywords: Donation, Hypertension, Kidney

Session Information

Date: Saturday, June 11, 2016

Session Name: Poster Session A: Kidney Donor Outcomes

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Halls C&D

Related Abstracts
  • Should Renin Angiotensin Blockade Be the Mainstay of Hypertension Treatment in Kidney Donors?
  • APOL1 High-Risk Genotype in African American Live Kidney Donors Is Not Associated With Post-Donation Development of Hypertension and Kidney Disease

The aim of this analysis is to describe the general epidemiological features for the development of hypertension and the most frequent medical therapies prescribed in a cohort of living kidney donors.

Of the 4267 living kidney donors spanning 1963-2014, 1121 (26.3%) developed post-donation hypertension. Figure 1 shows that at 7.2, 15.1 and 23.7 years post donation 25%, 50% and 75%, respectively develop hypertension.

Donors who developed hypertension were older at donation (40.4 (0.3) vs. 37.9 (0.2) years, p < 0.0001), have had longer followup time (28.9 (11) vs. 19.3 (12) years, p < 0.0001), smokers (36% vs 32%), had a higher BMI (26.2 (0.1) vs. 25.6 (0.1) kg/m2, p = 0.0004); and a lower eGFR (93.3 (0.5) vs. 95.9 (0.3) mL/min, p < 0.0001). In addition, they also had higher donation systolic (120.9 (0.4) vs. 118.6 (0.2) mmHg, p < 0.0001) and diastolic (75.3 (0.3) vs. 72.1 (0.2) mmHg, p < 0.0001) blood pressures, greater blood glucose (95.5 (0.5) vs 92.8 (0.3) mg/dL, p < 0.0001) and greater blood triglycerides (136.0 (4.4) vs. 119.6 (2.4) mg/dL, p = 0.001). Family history of hypertension was not different between hypertensive and non-hypertensive donors.

Angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) were used as the only medication in 28% and 11% of hypertensive donors, respectively. In 24% of hypertensive donors a diuretic was used as the only medication followed by calcium channel blockers (15.1%) and vasodilators (16.1%). In 31% of cases ACE inhibitors or ARB are combined with a diuretic, a calcium channel blocker or a vasodilator.

Donors who developed hypertension, at last follow-up, are also more likely to have significant proteinuria (14.5% vs. 2.8%), have lower eGFR (65.2 (0.6) vs. 65.5 (0.3), p = 0.0001), are at higher relative risk of ESRD (2.20, 95% CI: 0.99, 4.91, p = 0.05) and cardiovascular disease (4.3, 95% CI: 3.6, 5.2), but not death (p = 0.3) after adjusting for demographic factors.

Conclusion: Risk factors for the development of hypertension are similar to those observed in non-donor population. Assuringly, ACE-inhibition and ARB are the most commonly used anti-hypertensives but this proportion, one would argue, should be 100%.

CITATION INFORMATION: Ferrara L, Sanchez O, Berglund D, Matas A, Ibrahim H. Landscape of Hypertension Treatment in Former Kidney Donors. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Ferrara L, Sanchez O, Berglund D, Matas A, Ibrahim H. Landscape of Hypertension Treatment in Former Kidney Donors. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/landscape-of-hypertension-treatment-in-former-kidney-donors/. Accessed March 6, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Role of Mitochondria, Metabolism and Inflammation: Pathways Influencing Short Term Outcomes Post-Renal Transplantation
    • Factors Influencing Creatinine Rise Following Donor Nephrectomy

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.